Lung Cancer

Skip to main content

Lung Cancer, FDA Updates

Opdivo plus Yervoy and Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

Lung Cancer, FDA Updates

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

Lung Cancer, FDA Updates

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

From the Literature, Lung Cancer

First-Line Osimertinib Therapy Boosts Overall Survival in Non–Small-Cell Lung Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Case Reports, Immunotherapy, Lung Cancer

Rapid Onset of Severe Transaminitis in a Patient with Non–Small-Cell Lung Cancer After First Dose of Nivolumab 480 mg

Matthew Stankowicz, PharmD, BS, Megan Banaszynski, PharmD, BCOP, Russell Crawford, RPh, BCOP

Matthew Stankowicz, PharmD, BS; Megan Banaszynski, PharmD, BCOP; Russell Crawford, RPh, BCOP

Lung Cancer, Thyroid Cancer, FDA Updates

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Lung Cancer

Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC

Leukemia, Lung Cancer, Lymphoma, FDA Updates

November 25, 2019 – Oncology News & Updates

FDA Updates, Lung Cancer

Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

Loretta Fala, Medical Writer

FDA Updates, Lung Cancer

Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation

Loretta Fala, Medical Writer

8
9
10
11
12

Page 11 of 12
Results 101 - 110 of 116